BPG is committed to discovery and dissemination of knowledge
Featured Articles
9/27/2022 1:15:37 PM | Browse: 400 | Download: 1297
 |
Received |
|
2022-06-20 14:31 |
|
Peer-Review Started |
|
2022-06-20 14:35 |
|
First Decision by Editorial Office Director |
|
2022-07-14 08:27 |
|
Return for Revision |
|
2022-07-14 08:27 |
|
Revised |
|
2022-07-18 14:58 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2022-08-24 02:59 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2022-08-24 19:20 |
|
Articles in Press |
|
2022-08-24 19:20 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-09-14 12:46 |
|
Publish the Manuscript Online |
|
2022-09-27 13:00 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Hematology |
| Manuscript Type |
Case Report |
| Article Title |
Sudden extramedullary and extranodal Philadelphia-positive anaplastic large-cell lymphoma transformation during imatinib treatment for CML: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Qiong Wu, Yong Kang, Jing Xu, Wen-Can Ye, Zhen-Jiang Li, Wen-Feng He, Yuan Song, Qing-Ming Wang, Ai-Ping Tang and Ting Zhou |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Jiangxi “5511” Science and Technology Innovation Talent Project |
20171BCB18003 |
|
| Corresponding Author |
Zhen-Jiang Li, PhD, Chief Doctor, Department of Hematology, The Second Affiliated Hospital of Nanchang University, No. 1 Minde Road, Nanchang 330006, Jiangxi Province, China. lzjdgh@163.com |
| Key Words |
Chronic myeloid leukemia; BCR-ABL fusion gene; Imatinib mesylate; Anaplastic large-cell lymphoma; Philadelphia-positive; Nilotinib; Case report |
| Core Tip |
We describe a patient with chronic myeloid leukemia (CML) whose disease underwent a sudden transformation to anaplastic large-cell lymphoma (ALCL) following partial cytogenetic remission and early molecular response with 7 months of imatinib treatment. The patient developed a mass and felt pain in her left shoulders; a biopsy of the mass revealed ALCL, and BCR/ABL fusion was detected via fluorescence in situ hybridization. The patient was then treated with nilotinib and achieved complete cytogenetic remission and undetectable molecular residual disease within 6 mo. To the best of our knowledge, our patient is the first reported to have Philadelphia-positive ALCL transformed from CML. |
| Publish Date |
2022-09-27 13:00 |
| Citation |
Wu Q, Kang Y, Xu J, Ye WC, Li ZJ, He WF, Song Y, Wang QM, Tang AP, Zhou T. Sudden extramedullary and extranodal Philadelphia-positive anaplastic large-cell lymphoma transformation during imatinib treatment for CML: A case report. World J Clin Cases 2022; 10(28): 10339-10345 |
| URL |
https://www.wjgnet.com/2307-8960/full/v10/i28/10339.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v10.i28.10339 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
